Ronnie Aronson

Ronnie Aronson

Auto-generated profile, based on publicly available information

Ronnie Aronson

LMC Diabetes & Endocrinology Toronto Ontario Canada

Research Focus & Metrics

Academic Career Length

15Years (2012-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 September 2014 in Diabetes Care
Verified
Journal Article
Open access
RARonnie Aronson
Ronnie Aronson
PGPeter A. Gottlieb
Peter A. Gottlieb
JCJens S. Christiansen
Jens S. Christiansen
TDThomas W. Donner
Thomas W. Donner
EBEmanuele Bosi
Emanuele Bosi
TGthe DEFEND Investigator Group
the DEFEND Investigator Group
OBJECTIVE: Previous studies demonstrated that the anti-CD3 monoclonal antibody otelixizumab, administered at a total dose of 48–64 mg, can slow the loss of C-peptide in recent-onset type 1 diabetes patients, with frequent reactivation of Epstein Barr virus (EBV). The DEFEND-1 (Durable Response Therapy Evaluation for Early or New-Onset Type 1 Diabetes) trial was designed to test whether a lower dose of otelixizumab could preserve C-peptide secretion in new-onset type 1 diabetes patients. RESEARCH DESIGN AND METHODS: A multicenter, randomized, placebo-controlled trial was performed in sites in the U.S., Canada, and Europe. Two hundred eighty-one patients were randomized to treatment with 3.1 mg otelixizumab administered over 8 days or placebo. The primary end point of the study was the change in C-peptide area under the curve (AUC) from a 2-h mixed-meal tolerance test at month 12. RESULTS: The change in 2-h C-peptide AUC was not different between placebo-treated patients and otelixizumab-treated patients (−0.20 vs. −0.22 nmol/L, P = 0.81). Secondary end points, including HbA1c, glucose variability, and insulin dose, were also not statistically different between the two groups. More patients in the otelixizumab group than in the placebo group experienced adverse events, mostly grade 1 or grade 2. There was no EBV reactivation (viral load >10,000 copies/106 peripheral blood mononuclear cells) in the otelixizumab group, in contrast with previously published studies at higher doses of otelixizumab. CONCLUSIONS: Otelixizumab was well tolerated in patients with recent-onset type 1 diabetes at a total dose of 3.1 mg, but did not achieve preservation of levels of C-peptide or other markers of metabolic control.

11 January 2023 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
RARonnie Aronson
Ronnie Aronson
RBRuth E. Brown
Ruth E. Brown
LCLisa Chu
Lisa Chu
HBHarpreet S. Bajaj
Harpreet S. Bajaj
HKHasnain Khandwala
Hasnain Khandwala
RGRonald Goldenberg
Ronald Goldenberg
Aim: To examine the efficacy and patient satisfaction of intermittently scanned continuous glucose monitoring (isCGM) in adults using non‐insulin therapies for the management of type 2 diabetes. Materials and Methods: The IMMEDIATE study was a multisite, open label, randomized controlled trial with follow‐up at 16 weeks. Adults with type 2 diabetes using at least one non‐insulin therapy, with an HbA1c of 7.5% or higher (≥ 58 mmol/mol), were randomized 1:1 to receive an isCGM device plus diabetes self‐management education (isCGM + DSME) or DSME alone. Enrolment occurred from 8 September 2020 to 24 December 2021. The primary outcome was percentage mean time in range (TIR), in the final 2‐week period, measured via blinded CGM. Results: One hundred and sixteen participants were randomized (mean age, 58 years; diabetes duration, 10 years; mean HbA1c, 8.6% [70 mmol/mol]). At 16 weeks of follow‐up, the isCGM and DSME arm had a significantly greater mean TIR by 9.9% (2.4 hours) (95% CI, −17.3% to −2.5%; P < .01), significantly less time above range by 8.1% (1.9 hours) (95% CI, 0.5% to 15.7%; P = .037), and a greater reduction in mean HbA1c by 0.3% (3 mmol/mol) (95% CI, 0% to 0.7%; P = .048) versus the DSME arm. Time below range was low and not significantly different between groups and hypoglycaemic events were few in both groups. Glucose monitoring satisfaction was higher among isCGM users (adjusted difference −0.5 [95% CI, −0.7 to −0.3], P < .01). Conclusions: The IMMEDIATE study has shown that among non‐insulin–treated individuals with type 2 diabetes, use of isCGM is associated with an improvement in glycaemic outcomes.

23 February 2018 in Diabetes, Obesity and Metabolism
Verified
Journal Article
Open access
PDF file
RARonnie Aronson
Ronnie Aronson
JFJuan Frias
Juan Frias
AGAllison Goldman
Allison Goldman
ADAmanda Darekar
Amanda Darekar
BLBrett Lauring
Brett Lauring
STSteven G. Terra
Steven G. Terra
Aim: This phase III, multicentre, randomized study ( ClinicalTrials.gov ; NCT01958671) evaluated the efficacy and safety of ertugliflozin monotherapy in adults with inadequately controlled type 2 diabetes (glycated haemoglobin [HbA1c], 7.0% to 10.5% [53‐91 mmol/mol]) despite diet and exercise. Materials and methods: The 52‐week study comprised a 26‐week, double‐blind, placebo‐controlled period (Phase A) during which 461 participants received placebo, ertugliflozin 5 mg/d or ertugliflozin 15 mg/d. This was followed by a 26‐week active‐controlled period (Phase B) during which participants in the placebo group who had not received glycaemic rescue therapy had blinded metformin added. Results to Week 52 are reported. Because of the use of metformin in Phase B, no statistical comparisons of efficacy were made between the ertugliflozin and placebo/metformin groups at Week 52. Results: The mean (standard error) change from baseline to Week 52 in HbA1c was −0.9% (0.1) and −1.0% (0.1) in the ertugliflozin 5 and 15 mg groups, respectively. The proportions of participants with HbA1c <7.0% at Week 52 were 25.6% and 28.5%, respectively. Ertugliflozin reduced fasting plasma glucose, body weight and systolic blood pressure (SBP). The incidence of genital mycotic infections (GMIs) in females was significantly higher in both ertugliflozin groups (5 mg, 26.9%; 15 mg, 29.0%) vs the placebo/metformin group (9.9%), and in males was significantly higher in the 15 mg group (7.8%) vs the placebo/metformin group (1.2%). Ertugliflozin was not associated with increased incidence of urinary tract infections, symptomatic hypoglycaemia or hypovolaemia adverse events compared with placebo/metformin. Conclusions: Ertugliflozin treatment over 52 weeks improved glycaemic control and reduced body weight and SBP, but increased GMIs.

1 August 2012 in Diabetes Technology & Therapeutics
Verified
Journal Article
Open access
RARonnie Aronson
Ronnie Aronson
Despite the recognized importance of optimal insulin therapy, patient adherence to insulin therapy is an ongoing clinical care challenge. Insulin omission continues to be frequent and underestimated and has been correlated with poorer glycemic control and increased rates of diabetes-related complications. Insulin users consistently indentify multiple factors that contribute to insulin injection-related anxiety and to non-adherence. Injection-related discomfort continues to bear a significant contribution. Over the last decade, with advances in needle manufacturing technology, shorter and narrower needles have been associated with progressively improving patient self-rating of injection discomfort. Consequently, patient surveys of insulin users show discomfort to rank in the bottom third of significant contributors by prevalence. However, healthcare providers (HCP) and family member care providers continue to demonstrate a high level of anticipated and perceived pain for the patient. HCP anxiety and pain anticipation are each associated with patient anxiety and may therefore play a significant contributing role in patient non-adherence.

19 November 2018 in Diabetes Care
Verified
Journal Article
Open access
PDF file
RARonnie Aronson
Ronnie Aronson
RBRuth E. Brown
Ruth E. Brown
ALAihua Li
Aihua Li
MRMichael C Riddell
Michael C Riddell
OBJECTIVE: Postexercise hyperglycemia, following high-intensity interval training (HIIT) in patients with type 1 diabetes (T1D), is largely underrecognized by the clinical community and generally undertreated. The aim of this study was to compare four multipliers of an individual’s insulin correction factor (ICF) to treat post-HIIT hyperglycemia. RESEARCH DESIGN AND METHODS: The FIT study had a randomized, crossover design in physically active subjects with T1D (mean ± SD age 34.9 ± 10.1 years, BMI 25.5 ± 2.5 kg/m2, and HbA1c 7.2 ± 0.9%) using multiple daily injections. Following an 8-week optimization period, with 300 units/mL insulin glargine used as the basal insulin, subjects performed four weekly sessions of 25 min of HIIT. If hyperglycemia (>8.0 mmol/L) resulted, subjects received a bolus insulin correction 15 min post-HIIT, based on their own ICF, adjusted by one of four multipliers: 0, 50, 100, or 150%. RESULTS: Seventeen subjects completed 71 exercise trials, of which 64 (90%) resulted in hyperglycemia. At 40 min postexercise, plasma glucose (PG) increased from mean ± SD 8.8 ± 1.0 mmol/L at baseline to 12.7 ± 2.4 mmol/L (increase of 3.8 ± 1.5 mmol/L). After correction, adjusted mean ± SE PG was significantly reduced for the 50% (−2.3 ± 0.8 mmol/L, P < 0.01), 100% (−4.7 ± 0.8 mmol/L, P < 0.001), and 150% (−5.3 ± 0.8 mmol/L, P < 0.001) arms but had increased further in the 0% correction arm. Both the 100 and 150% corrections were more effective than the 50% correction (P < 0.01 and P < 0.001, respectively) but were not different from each other. Hypoglycemia was rare. CONCLUSIONS: In post-HIIT hyperglycemia, correction based on a patient’s usual ICF is safe and effective. Optimal PG reduction, with minimal hypoglycemia, occurred in the 100 and 150% correction arms.

1 August 2017 in Diabetes Research and Clinical Practice
Verified
Journal Article
Open access
KKKamlesh Khunti
Kamlesh Khunti
SASaud Alsifri
Saud Alsifri
RARonnie Aronson
Ronnie Aronson
Maja Cigrovski BerkovicMaja Cigrovski Berkovic
Maja Cigrovski Berkovic
CECatherine Enters-Weijnen
Catherine Enters-Weijnen
ARAmbady Ramachandran
Ambady Ramachandran
Data on the impact of hypoglycaemia on patients' daily lives and diabetes self-management, particularly in developing countries, are lacking. The aim of this study was to assess fear of, and responses to, hypoglycaemia experienced by patients globally. This non-interventional, multicentre, 4-week prospective study using self-assessment questionnaires and patient diaries consisted of 27,585 patients, ≥18years, with type 1 diabetes (n=8022) or type 2 diabetes (n=19,563) treated with insulin for >12months, at 2004 sites in 24 countries worldwide. Increased blood glucose monitoring (69.7%) and seeking medical assistance (62.0%) were the most common responses in the 4weeks following hypoglycaemic events for patients with type 1 diabetes and type 2 diabetes, respectively. Approximately 44% of patients with type 1 diabetes or type 2 diabetes increased calorie intake in response to a hypoglycaemic episode. Following hypoglycaemia, 3.9% (type 1 diabetes) and 6.2% (type 2 diabetes) of patients took leave from work or study. Regional differences in fear of, and responses to, hypoglycaemia were evident - in particular, a lower level of hypoglycaemic fear and utilisation of healthcare resources in Northern Europe and Canada. Hypoglycaemia has a major impact on patients and their behaviour. These global data for the first time reveal regional variations in response to hypoglycaemia and highlight the importance of patient education and management strategies.